LIVE BETA · GROQ + NEO4J

From cell to cure.
Calibrated for India.

The biomedical intelligence platform that connects 4.3M relationships, looks at a cell image, reasons over Indian genetics, and tells you what it means for an Indian patient — including what to do about it.

Open Query Interface →🔬 Try Vision Module

Powered by Llama 3.3 70B · Neo4j · PrimeKG · IMPPAT · IndiGen · ClinicalTrials.gov

4.4M+
Biomedical relationships
PrimeKG + IMPPAT + IndiGen + CTRI
100
Ayurvedic compounds curated
Full IMPPAT 17,967 via ACTREC in progress · see /methods
180
Indian clinical trials
ClinicalTrials.gov, CTRI
1.4B
People. One platform.
India-first by design

Global biomedical AI is built on Western genetics.
India has different genetics. Different diseases. Different medicines.

🧬
Population genetics gap

CYP2C19*2 loss-of-function affects 23% of South Asians vs 15% globally. Standard clopidogrel dosing is wrong for 300M Indians. No global KG knows this.

🌿
Traditional medicine gap

17,967 Ayurvedic phytochemicals catalogued in IMPPAT 2.0. Zero mechanistic evidence in any global knowledge graph. CDSCO requires computational validation — no tool provides it. We have curated 100 high-export compounds; full ingestion via ACTREC academic agreement in progress.

🔬
Image analysis gap

India has 3,000 pathologists for 1.4B people. Retinal fundus cameras are everywhere. No tool connects the image to Indian genetic context and treatment pathways.

Four specialised engines. One platform.

💊
Module A
Open →

Drug Repurposing Scanner

Find FDA-approved drugs with mechanistic connections to any disease — through protein targets, shared pathways, and Indian genetic context. Multi-hop paths, not guesses.

MDR-TuberculosisDiabetic TBKala-azarDengue
🌿
Module B
Open →

Ayurvedic Validation Engine

Generate computational mechanism certificates for IMPPAT phytochemicals. Protein binding → pathway → disease evidence for CDSCO and EU regulatory submissions.

CurcuminQuercetinBerberineWithaferin A
🧬
Module C
Open →

Indian Pharmacogenomics

CYP2C19*2 is 23% in South Asia vs 15% globally. Standard guidelines are wrong for 300M Indians. Explore how Indian-enriched variants change drug dosing and selection.

CYP2C19G6PDTPMTCYP2D6
🔬
Vision
Open →

PetriDish Vision

Upload a retinal fundus, blood smear, or biopsy. AI extracts biomarkers, maps them to the knowledge graph, and returns treatment paths with active Indian trial data.

Diabetic RetinopathyP. falciparumHER2+ CancerTB AFB

Image or text in. Evidence-graded intelligence out.

01
Ask or Upload
Natural language question or biomedical image
02
LLM generates
Llama 3.3 70B writes precise Neo4j Cypher
03
Graph traverses
4.3M edges traced — drugs, genes, pathways
04
India overlay
Variant frequencies, Ayurvedic compounds, trials
05
Report generated
Evidence-graded answer + PDF export
NEW · PetriDish Vision

Upload an image.
Get a treatment plan.

Retinal fundus → DR grade + VEGF pathway drugs + CYP2C19 warning. Blood smear → P. falciparum vs vivax + G6PD alert + artemisinin protocol. Biopsy → HER2 status + active Indian trials. All in under 60 seconds.

Try Vision Module →
VISION ANALYSIS — RETINAL FUNDUS
DR Grade
3 — Severe NPDR
Macular Oedema
Present (centre)
VEGF Signal
Upregulated
Confidence
94%
→ Ranibizumab (anti-VEGF, 1st line) · ⚠ rs699947 (31% India)
PrimeKGHarvard MIMS
IMPPAT 2.0ACTREC Mumbai
IndiGenCSIR-IGIB
GenomeIndiaDBT
DrugBankWishart Lab
UniProtSwiss-Prot
ReactomeEMBL-EBI
PharmGKBStanford
ClinicalTrials.govNLM/NIH
CTRI IndiaICMR

The platform that does not exist yet.
Until now.

No login. No waitlist. Open during beta.

Start Querying →Batch Analysis (20 compounds)